CSF2 and experimental autoimmune encephalomyelitis: It is well documented that a VLA-4 blockade targets Th1 cells, leading to a reduction in the levels of IFNγ, TNFα/β and GM-CSF at the inflammation site, including the CNS during experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis (MS)42–45.